Hepatitis Monthly

Published by: Kowsar

SHFI: A Novel Noninvasive Predictive Model for Significant Fibrosis in Patients With Chronic Hepatitis B

Fatma Demet Arslan 1 , * , Inanc Karakoyun 1 , Bengu Tatar 2 , Emel Ebru Pala 3 , Mustafa Yıldırım 4 , Celal Ulasoglu 5 , Can Duman 1 , Harun Akar 4 , Sukran Kose 2 and Banu Isbilen Basok 1
Authors Information
1 Department of Medical Biochemistry, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey
2 Clinic of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey
3 Department of Medical Pathology, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey
4 Clinic of Internal Medicine, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey
5 Clinic of Gastroenterology, Istanbul Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey
Article information
  • Hepatitis Monthly: February 2018, 18 (2); e63310
  • Published Online: February 10, 2018
  • Article Type: Research Article
  • Received: October 27, 2017
  • Revised: January 22, 2018
  • Accepted: February 3, 2018
  • DOI: 10.5812/hepatmon.63310

To Cite: Arslan F D, Karakoyun I, Tatar B, Pala E E, Yıldırım M, et al. SHFI: A Novel Noninvasive Predictive Model for Significant Fibrosis in Patients With Chronic Hepatitis B, Hepat Mon. 2018 ; 18(2):e63310. doi: 10.5812/hepatmon.63310.

Copyright © 2018, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. WHO . World Health Organization, Hepatitis B. 2017. Available from: http://www.who.int/mediacentre/factsheets/fs204/en/..
  • 2. European Association for Study of L. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237. doi: 10.1016/j.jhep.2015.04.006. [PubMed: 25911335].
  • 3. Liu T, Wang X, Karsdal MA, Leeming DJ, Genovese F. Molecular serum markers of liver fibrosis. Biomark Insights. 2012;7:105-17. doi: 10.4137/BMI.S10009. [PubMed: 22872786].
  • 4. Fallatah SM. Successful management of complex regional pain syndrome type 1 using single injection interscalene brachial plexus block. Saudi J Anaesth. 2014;8(4):559-61. doi: 10.4103/1658-354X.140903. [PubMed: 25422619].
  • 5. Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011;11:91. doi: 10.1186/1471-230X-11-91. [PubMed: 21849046].
  • 6. Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol. 2006;12(23):3682-94. [PubMed: 16773685].
  • 7. Sebastiani G. Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms. World J Gastroenterol. 2009;15(18):2190-203. [PubMed: 19437558].
  • 8. Jarcuska P, Janicko M, Veseliny E, Jarcuska P, Skladany L. Circulating markers of liver fibrosis progression. Clin Chim Acta. 2010;411(15-16):1009-17. doi: 10.1016/j.cca.2010.04.009. [PubMed: 20399764].
  • 9. Pinzani M, Vizzutti F, Arena U, Marra F. Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol. 2008;5(2):95-106. doi: 10.1038/ncpgasthep1025. [PubMed: 18253138].
  • 10. Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol. 2005;42 Suppl(1):S22-36. doi: 10.1016/j.jhep.2004.12.008. [PubMed: 15777570].
  • 11. Tacke F, Weiskirchen R. Update on hepatic stellate cells: pathogenic role in liver fibrosis and novel isolation techniques. Expert Rev Gastroenterol Hepatol. 2012;6(1):67-80. doi: 10.1586/egh.11.92. [PubMed: 22149583].
  • 12. Rockey DC. Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis. 2001;21(3):337-49. doi: 10.1055/s-2001-17551. [PubMed: 11586464].
  • 13. Iredale JP, Thompson A, Henderson NC. Extracellular matrix degradation in liver fibrosis: Biochemistry and regulation. Biochim Biophys Acta. 2013;1832(7):876-83. doi: 10.1016/j.bbadis.2012.11.002. [PubMed: 23149387].
  • 14. Liang B, Li Y, Zhao A, Xie F, Guo Z. Clinical utility of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 concentrations in the assessment of liver fibrosis due to chronic hepatitis B. J Int Med Res. 2012;40(2):631-9. doi: 10.1177/147323001204000225. [PubMed: 22613424].
  • 15. Sumer S, Aktug Demir N, Kolgelier S, Cagkan Inkaya A, Arpaci A, Saltuk Demir L, et al. The Clinical Significance of Serum Apoptotic Cytokeratin 18 Neoepitope M30 (CK-18 M30) and Matrix Metalloproteinase 2 (MMP-2) Levels in Chronic Hepatitis B Patients with Cirrhosis. Hepat Mon. 2013;13(6). e10106. doi: 10.5812/hepatmon.10106. [PubMed: 24032040].
  • 16. Passino MA, Adams RA, Sikorski SL, Akassoglou K. Regulation of hepatic stellate cell differentiation by the neurotrophin receptor p75NTR. Science. 2007;315(5820):1853-6. doi: 10.1126/science.1137603. [PubMed: 17395831].
  • 17. Asai K, Tamakawa S, Yamamoto M, Yoshie M, Tokusashi Y, Yaginuma Y, et al. Activated hepatic stellate cells overexpress p75NTR after partial hepatectomy and undergo apoptosis on nerve growth factor stimulation. Liver Int. 2006;26(5):595-603. doi: 10.1111/j.1478-3231.2006.01267.x. [PubMed: 16762005].
  • 18. Kendall TJ, Hennedige S, Aucott RL, Hartland SN, Vernon MA, Benyon RC, et al. p75 Neurotrophin receptor signaling regulates hepatic myofibroblast proliferation and apoptosis in recovery from rodent liver fibrosis. Hepatology. 2009;49(3):901-10. doi: 10.1002/hep.22701. [PubMed: 19072833].
  • 19. Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med. 2003;163(2):218-24. [PubMed: 12546613].
  • 20. Liu CH, Lin JW, Tsai FC, Yang PM, Lai MY, Chen JH, et al. Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. Liver Int. 2006;26(9):1087-94. doi: 10.1111/j.1478-3231.2006.01355.x. [PubMed: 17032409].
  • 21. Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol. 2007;13(4):525-31. [PubMed: 17278217].
  • 22. Vardar R, Vardar E, Demiri S, Sayhan SE, Bayol U, Yildiz C, et al. Is there any non-invasive marker replace the needle liver biopsy predictive for liver fibrosis, in patients with chronic hepatitis?. Hepatogastroenterology. 2009;56(94-95):1459-65. [PubMed: 19950810].
  • 23. Mohamadnejad M, Montazeri G, Fazlollahi A, Zamani F, Nasiri J, Nobakht H, et al. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. Am J Gastroenterol. 2006;101(11):2537-45. doi: 10.1111/j.1572-0241.2006.00788.x. [PubMed: 17029616].
  • 24. Cross TJ, Calvaruso V, Maimone S, Carey I, Chang TP, Pleguezuelo M, et al. Prospective comparison of Fibroscan, King's score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection. J Viral Hepat. 2010;17(8):546-54. doi: 10.1111/j.1365-2893.2009.01210.x. [PubMed: 19874477].
  • 25. Bruno R, Sacchi P, Cima S, Maiocchi L, Patruno SF, Klersy C, et al. Correlation between FIB4, liver stiffness and metabolic parameters in patients with HIV and hepatitis C virus co-infection. Dig Liver Dis. 2011;43(7):575-8. doi: 10.1016/j.dld.2011.03.009. [PubMed: 21596630].
  • 26. Hsieh YY, Tung SY, Lee IL, Lee K, Shen CH, Wei KL, et al. FibroQ: an easy and useful noninvasive test for predicting liver fibrosis in patients with chronic viral hepatitis. Chang Gung Med J. 2009;32(6):614-22. [PubMed: 20035640].
  • 27. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36(4 Pt 1):986-92. doi: 10.1053/jhep.2002.36128. [PubMed: 12297848].
  • 28. Chen B, Ye B, Zhang J, Ying L, Chen Y. RDW to platelet ratio: a novel noninvasive index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B. PLoS One. 2013;8(7). e68780. doi: 10.1371/journal.pone.0068780. [PubMed: 23874760].
  • 29. Ahmad W, Ijaz B, Javed FT, Gull S, Kausar H, Sarwar MT, et al. A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol. 2011;11:44. doi: 10.1186/1471-230X-11-44. [PubMed: 21507271].
  • 30. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127(6):1704-13. [PubMed: 15578508].
  • 31. Ishak K, Baptista A, Bianchi L. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-9.
  • 32. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837-45. [PubMed: 3203132].
  • 33. Wu SD, Wang JY, Li L. Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: a comparative study. World J Gastroenterol. 2010;16(4):501-7. [PubMed: 20101779].
  • 34. Eminler AT, Ayyildiz T, Irak K, Kiyici M, Gurel S, Dolar E, et al. AST/ALT ratio is not useful in predicting the degree of fibrosis in chronic viral hepatitis patients. Eur J Gastroenterol Hepatol. 2015;27(12):1361-6. doi: 10.1097/MEG.0000000000000468. [PubMed: 26352130].
  • 35. Karacaer Z, Avcı, O , Karadag, F. Y . King's Score may be More Effective in the Determination of Severe Fibrosis in Chronic Hepatitis B Infections. Viral Hepat J. 2017;23(1):20.
  • 36. Ucar F, Sezer S, Ginis Z, Ozturk G, Albayrak A, Basar O, et al. APRI, the FIB-4 score, and Forn's index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol. 2013;25(9):1076-81. doi: 10.1097/MEG.0b013e32835fd699. [PubMed: 23510962].
  • 37. Erdogan S, Dogan HO, Sezer S, Uysal S, Ozhamam E, Kayacetin S, et al. The diagnostic value of non-invasive tests for the evaluation of liver fibrosis in chronic hepatitis B patients. Scand J Clin Lab Invest. 2013;73(4):300-8. doi: 10.3109/00365513.2013.773592. [PubMed: 23514016].
  • 38. Liu XD, Wu JL, Liang J, Zhang T, Sheng QS. Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients. World J Gastroenterol. 2012;18(22):2784-92. doi: 10.3748/wjg.v18.i22.2784. [PubMed: 22719186].
  • 39. Coskun BD, Altinkaya E, Sevinc E. The diagnostic value of a globulin/platelet model for evaluating liver fibrosis in chronic hepatitis B patients. Rev Esp Enferm Dig. 2015;107(12):740-4.
  • 40. Kim BK, Kim HS, Park JY, Kim DY, Ahn SH, Chon CY, et al. Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B. PLoS One. 2012;7(7). e41964. doi: 10.1371/journal.pone.0041964. [PubMed: 22848675].
  • 41. Trembling PM, Lampertico P, Parkes J, Tanwar S, Vigano M, Facchetti F, et al. Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. J Viral Hepat. 2014;21(6):430-8. doi: 10.1111/jvh.12161. [PubMed: 24750297].
  • 42. Parikh P, Ryan JD, Tsochatzis EA. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Ann Transl Med. 2017;5(3):40. doi: 10.21037/atm.2017.01.28. [PubMed: 28251119].
  • 43. Fung J, Lai CL, Fong DY, Yuen JC, Wong DK, Yuen MF. Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver Int. 2008;28(10):1408-16. doi: 10.1111/j.1478-3231.2008.01784.x. [PubMed: 18482268].
  • 44. Zeng X, Xu C, He D, Li M, Zhang H, Wu Q, et al. Performance of several simple, noninvasive models for assessing significant liver fibrosis in patients with chronic hepatitis B. Croat Med J. 2015;56(3):272-9. [PubMed: 26088852].
  • 45. Parsian H, Alizadeh M, Yahyapour Y. Clinical application of non-invasive markers of liver fibrosis. Pract Manag Chronic Viral Hepat. 2013;InTech:92-109.
  • 46. Sporea I, Sirli R, Popescu A, Cornianu M, Manciu C, Focsa M. The quality of the fragment obtained by liver biopsy for staging chronic hepatitis. J Gastrointestin Liver Dis. 2007;16(3):263-6. [PubMed: 17925919].
  • 47. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut. 2006;55(3):403-8. doi: 10.1136/gut.2005.069153. [PubMed: 16020491].
  • 48. European Association for Study of L, Asociacion Latinoamericana para el Estudio del H. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-64. doi: 10.1016/j.jhep.2015.04.006. [PubMed: 25911335].
  • 49. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21(11):1020-6. doi: 10.1016/j.cmi.2015.06.028. [PubMed: 26163105].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments